Biogen (BIIB) vs Vaxcyte (PCVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Vaxcyte (PCVX) has outperformed Biogen (BIIB) over the past year, gaining 70.0% versus a gain of 50.9%. Over five years, PCVX leads with a +192.4% price change compared with -19.7% for BIIB. Biogen is the larger company by market cap ($33.35 billion vs $11.15 billion), about 3.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIIB | PCVX |
|---|---|---|
| Share price | $225.71 | $71.38 |
| Market cap | $33.35B | $11.15B |
| 1-day change | +3.33% | +9.79% |
| YTD return | +28.25% | +54.70% |
| 1-year return | +50.87% | +69.99% |
| 5-year return | -19.73% | +192.42% |
| P/E ratio (TTM) | 40.09 | — |
| Forward P/E | 13.65 | — |
| EPS (TTM) | $5.63 | $-8.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.89B | — |
| Revenue growth (YoY) | +2.22% | — |
| Net income (latest FY) | $1.29B | $-766.63M |
| Gross margin | 75.69% | — |
| Net margin | 13.07% | — |
| 52-week high | $230.49 | $90.75 |
| 52-week low | $138.00 | $39.87 |
| Distance from 52-week high | -2.07% | -21.34% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +5.52% | +63.91% |
| Average volume | 1.06M | 1.76M |
| Shares outstanding | 147.75M | 156.22M |
| Employees | 7,500 | 507 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Biogen is about 3.0 times larger than Vaxcyte by market value ($33.35B vs $11.15B).
- PCVX has outperformed BIIB by 19.1 percentage points over the past year.
About Biogen
BIIB stock →Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,500 employees
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
BIIB vs PCVX FAQ
Which is bigger, Biogen or Vaxcyte?
Biogen (BIIB) is larger, with a market capitalization of $33.35B compared with $11.15B for Vaxcyte (PCVX).
Which stock has performed better over the past year, BIIB or PCVX?
PCVX returned +69.99% over the past 12 months, compared with +50.87% for BIIB (price return, excluding dividends). Past performance does not predict future results.
Are Biogen and Vaxcyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.